Figure 2From: Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinibMaximal percent change in plasma protein concentration from C1D1 to C2D28 by patient. (A) sKIT. (B) VEGF-A. (C) sVEGFR-2. (D) sVEGFR-3. Light gray bars denote patients with triple-negative disease. Broken horizontal lines denote median values for each protein. C, cycle; D, day; sKIT, soluble KIT; sVEGFR, soluble vascular endothelial growth factor receptor; VEGF, vascular endothelial growth factor.Back to article page